Atm Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
ATM (Ataxia-Telangiectasia Mutated) is a serine/threonine protein kinase that functions as a master regulator of the DNA damage response. It is essential for maintaining genomic stability, cell cycle control, and cellular survival following DNA double-strand breaks. ATM is encoded by the ATM gene and belongs to the PI3K-like protein kinase (PI3KK) family, which also includes ATR and DNA-PKcs.
| Property | Value |
|---|---|
| Protein Name | ATM / Ataxia-Telangiectasia Mutated |
| Gene Symbol | ATM |
| UniProt ID | Q13315 |
| Molecular Weight | 350 kDa (3056 amino acids) |
| Structure | PI3K-like kinase domain, FAT, FATC domains |
| Expression | Ubiquitous, high in brain, testis, lymphoid tissue |
| Subcellular Localization | Nucleus (constitutively), cytoplasm (upon activation) |
ATM is a massive 3056-amino acid protein with a complex domain architecture. The N-terminal region contains multiple HEAT repeats that facilitate protein-protein interactions, while the C-terminal region houses the catalytic PI3K-like kinase domain flanked by the FAT and FATC domains that are characteristic of the PIKK family.
The ATM protein contains several critical structural domains:
HEAT Repeat Domain (1-900 aa): Contains approximately 30 HEAT repeats that form a superhelical structure capable of binding various proteins and DNA ends. This domain mediates interactions with numerous ATM substrates and regulatory proteins.
FATC Domain (2600-2700 aa): The C-terminal FAT domain wraps around the kinase domain and is essential for protein stability and function.
PI3K-like Kinase Domain (2700-3056 aa): The catalytic core that phosphorylates serine and threonine residues on target proteins. Contains the activation loop and the P+1 loop that determines substrate specificity.
NBS1 Binding Site: ATM interacts with the NBS1 subunit of the MRN complex through a specific binding interface, facilitating recruitment to DNA damage sites.
p53 Binding Domain: Direct interaction with p53 for phosphorylation and activation of this critical tumor suppressor.
The cryo-EM structure of ATM has revealed an autoinhibited conformation in which the kinase domain is held in an inactive state. DNA damage-induced autophosphorylation triggers a major conformational change that releases the kinase domain for substrate access.
ATM is the central kinase in the DNA damage response, functioning as a molecular watchman that monitors genomic integrity:
ATM exists as an inactive dimer in unstressed cells. Upon detection of DNA double-strand breaks (DSBs), ATM undergoes rapid autophosphorylation at serine 1981, causing dissociation into active monomers. This activation is mediated by the MRN complex (MRE11-RAD50-NBS1), which recruits ATM to damage sites and stimulates its kinase activity.
Once activated, ATM phosphorylates over 100 downstream substrates, creating a phosphorylation cascade that amplifies the DNA damage signal:
ATM implements cell cycle checkpoints to allow time for DNA repair:
When DNA damage is irreparable, ATM triggers programmed cell death through:
ATM ensures long-term genomic integrity through:
ATM exhibits tissue-specific and developmental regulation:
ATM is expressed throughout the brain with highest levels in:
Neuronal ATM expression is upregulated during development and remains high in adulthood, reflecting the constant demand for DNA repair in post-mitotic neurons.
Biallelic loss-of-function mutations in ATM cause AT, a devastating childhood disorder:
ATM dysfunction is increasingly recognized in AD pathogenesis:
ATM involvement in PD is an emerging area of research:
Neurons are particularly vulnerable to DNA damage due to:
ATM deficiency accelerates DNA damage accumulation, leading to:
ATM integrates oxidative stress and DNA damage responses:
ATM localizes to mitochondria and regulates:
ATM can phosphorylate tau at multiple sites:
| Approach | Strategy | Status | References |
|---|---|---|---|
| ATM activators | Small molecules to enhance ATM function | Preclinical | Yang 2010, Quick 2018 |
| Gene therapy | AAV-mediated ATM delivery | Research | 2021-2023 |
| Combination therapy | ATM activators + antioxidants | Preclinical | Botero 2019 |
| p53 stabilizers | Enhance downstream signaling | Discovery | 2020 |
| Approach | Strategy | Status | References |
|---|---|---|---|
| ATM inhibitors | Sensitize tumors to radiation | Phase I/II | 2019-2022 |
| Synthetic lethality | PARP inhibitor combinations | Approved | 2021 |
| Biomarker development | ATM as predictive marker | Clinical | 2020 |
Current frontiers in ATM research include:
[1] Yang JL, et al. DNA damage and its relationship to Alzheimer's disease. J Neurochem. 2010;113:441-456. PMID:20085609
[2] Quick KL, et al. ATM deficiency in the Alzheimer's disease brain. Neurobiol Aging. 2018;62:187-200. PMID:29246732
[3] Botero V, et al. ATM regulates neuronal survival under oxidative stress. Cell Death Discov. 2019;5:79. PMID:31044021
[4] Song P, et al. ATM in Parkinson's disease: new therapeutic targets. Mov Disord. 2021;36:1123-1134. PMID:33460432
[5] Gatti R, et al. Ataxia-telangiectasia: from genetics to therapy. Nat Rev Dis Primers. 2022;8:3. PMID:35039562
[6] Shiloh Y, et al. The ATM protein and the cellular stress response. Cold Spring Harb Symp Quant Biol. 2021;86:1-15. PMID:34580123
[7] McKinnon PJ, et al. DNA repair and the molecular biology of ATM deficiency. DNA Repair. 2020;93:102917. PMID:32949876
[8] Liu J, et al. ATM activation and signaling in neurodegeneration. Cell Mol Neurobiol. 2023;43:1245-1262. PMID:36789452
The study of Atm Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] Yang JL, et al. DNA damage and its relationship to Alzheimer's disease. J Neurochem. 2010;113(2):441-456. PMID:20085609
[2] Quick KL, et al. ATM deficiency in the Alzheimer's disease brain. Neurobiol Aging. 2018;62:187-200. PMID:29246732
[3] Botero V, et al. ATM regulates neuronal survival under oxidative stress. Cell Death Discov. 2019;5(1):79. PMID:31044021
[4] Song P, et al. ATM in Parkinson's disease: new therapeutic targets. Mov Disord. 2021;36(5):1123-1134. PMID:33460432
[5] Gatti R, et al. Ataxia-telangiectasia: from genetics to therapy. Nat Rev Dis Primers. 2022;8(1):3. PMID:35039562
[6] Shiloh Y, et al. The ATM protein and the cellular stress response. Cold Spring Harb Symp Quant Biol. 2021;86:1-15. PMID:34580123
[7] McKinnon PJ, et al. DNA repair and the molecular biology of ATM deficiency. DNA Repair. 2020;93:102917. PMID:32949876
[8] Liu J, et al. ATM activation and signaling in neurodegeneration. Cell Mol Neurobiol. 2023;43(4):1245-1262. PMID:36789452